- $1.21bn
- $1.19bn
- $174.54m
Annual balance sheet for Enfusion, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 5.9 | 13.9 | 64.4 | 62.5 | 35.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.97 | 12.2 | 18.2 | 25.9 | 28.1 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16.2 | 28.9 | 89.7 | 96.8 | 69.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.01 | 8.78 | 13.1 | 22.5 | 32.6 |
| Other Long Term Assets | |||||
| Total Assets | 23.2 | 39.1 | 106 | 124 | 109 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.07 | 10.7 | 8.11 | 17.4 | 20.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 36 | 107 | 50.8 | 58.8 | 55.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -12.8 | -68 | 55.3 | 65 | 53.7 |
| Total Liabilities & Shareholders' Equity | 23.2 | 39.1 | 106 | 124 | 109 |
| Total Common Shares Outstanding |